Annual Congress 2023 of the European Academy of Allergy and Clinical Immunology: Groundbreaking Study Validates Allergen Exposure Chamber for Assessing Clinical Outcomes of HDM AIT in Allergic Rhinoconjunctivitis Patients'
2023-06-11
临床结果免疫疗法临床研究
HAMBURG, Germany, June 11, 2023 /PRNewswire/ -- A study conducted by researchers from the ALL-MED Medical Research Institute and the Department of Clinical Immunology at Wroclaw Medical University in Poland has validated the use of an allergen exposure chamber (AEC) in assessing the clinical outcomes of house dust mite (HDM) allergen immunotherapy (AIT) in patients with allergic rhinoconjunctivitis.
The study focused on evaluating the efficacy and safety of AEC-derived clinical outcomes of subcutaneous HDM AIT, a treatment designed to alleviate symptoms triggered by HDM allergies. Fifty patients with HDM-triggered allergic rhinoconjunctivitis were included in the study, with HDM allergy confirmed through various diagnostic tests such as skin prick tests, serum-specific IgE, and basophil activation tests.
During the study, patients were assessed in the allergen exposure chamber before commencing AIT and after 12 months of treatment. The chamber provided a controlled environment, allowing patients to be exposed to HDM allergen under stable and well-regulated conditions. Various clinical endpoints, including total nasal symptom score (TNSS), visual analog scale (VAS), and objective parameters such as acoustic rhinometry, peak nasal inspiratory flow (PNIF), and nasal secretion weight, were used to assess the effectiveness of AIT.
The results of the study demonstrated a statistically significant reduction in TNSS (phttps://review.jove.com/v/64801?status=a66807k
In conclusion, the study confirms that the allergen exposure chamber challenge is an effective, reproducible, and safe method for assessing the outcomes of HDM AIT in patients with allergic rhinoconjunctivitis. Ongoing research is being conducted to validate clinical endpoints using immunological biomarkers, offering promising prospects for improved diagnostic and treatment approaches.
About EAACI:
The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956. EAACI is dedicated to improving the health of people affected by allergic diseases. With more than 15 000 members from 125 countries and over 75 National Allergy Societies, EAACI is the primary source of expertise in Europe and worldwide for all aspects of allergy.
Contact:
EAACI Headquarters, Hagenholzstrasse 111, 3rd Floor 8050 Zurich, CH- Switzerland
Tel: +41799561865
[email protected]
www.eaaci.org
Logo: https://mma.prnewswire.com/media/2060385/EAACI_Logo.jpg
SOURCE EAACI
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。